| 期 |
栏目 |
标题 |
文件 |
| 卷 15, 编号 3 (2013) |
Articles |
Prognosticheskoe znachenie lokal'nogo i sistemnogo lecheniya pri rake molochnoy zhelezy I stadii |
|
| 卷 21, 编号 2 (2019) |
Articles |
The potential of using eribulin in patients with breast cancer, associated with brain metastasis: the scientific background and the Russian clinical experience |
(Rus)
|
| 卷 21, 编号 1 (2019) |
Articles |
Efficacy and safety of eribulin in HER2-negative metastatic breast cancer: the results of long-term experience in real clinical practice in Russia |
(Rus)
|
| 卷 21, 编号 1 (2019) |
Articles |
The potential use of oncolytic viruses in breast cancer: historical aspects and future prospects (literature review) |
(Rus)
|
| 卷 21, 编号 3 (2019) |
Articles |
Complex radiologic imaging of early breast cancer (literature review) |
(Rus)
|
| 卷 21, 编号 3 (2019) |
Articles |
The predictive value of digital mammography, breast ultrasound and their combination in the diagnosis of early breast cancer |
(Rus)
|
| 卷 21, 编号 3 (2019) |
Articles |
The efficacy of neoadjuvant chemotherapy and survival in older patients with stages II to III triple-negative breast cancer |
(Rus)
|
| 卷 22, 编号 1 (2020) |
CLINICAL ONCOLOGY |
Modern view on the issues of diagnosis and verification of axillary lymph nodes involvement in early breast cancer |
(Rus)
|
| 卷 22, 编号 2 (2020) |
Best Practice |
Prospects of eribulin administration for patients with HR-positive HER2-negative metastatic breast cancer after progression on CDK4/6 Inhibitors: theoretical background and first experience |
(Rus)
(Eng)
|
| 卷 23, 编号 1 (2021) |
CLINICAL ONCOLOGY |
Analysis of the efficacy and safety of eribulin therapy in patients with HR+/HER2- metastatic breast cancer pretreated with CDK4/6 inhibitors in real Russian practice |
(Rus)
(Eng)
|
| 卷 23, 编号 1 (2021) |
CLINICAL ONCOLOGY |
Prognostic role of clinical and biological factors and parameters of hormonal profile in patients with primary inoperable HER2-negative breast cancer |
(Rus)
|
| 卷 23, 编号 2 (2021) |
CLINICAL ONCOLOGY |
Biological features of ductal carcinoma in situ: clinical role and basis for treatment individualization |
(Rus)
|
| 卷 23, 编号 4 (2021) |
CLINICAL ONCOLOGY |
Features of response to modern neoadjuvant chemotherapy with dual anti-HER2 blockade (trastuzumab and pertuzumab) in the patients with HER2-positive breast cancer stage II–III |
(Rus)
|
| 卷 25, 编号 1 (2023) |
CLINICAL ONCOLOGY |
Following in the footsteps of SABCS 2022: top 16 early breast cancer studies that could change our clinical practice: A review |
(Rus)
|
| 卷 25, 编号 1 (2023) |
CLINICAL ONCOLOGY |
Following in the footsteps of SABCS 2022: top 12 advanced breast cancer studies that could change our clinical practice: A review |
(Rus)
|
| 卷 25, 编号 2 (2023) |
CLINICAL ONCOLOGY |
Hydroxyethyldimethyldihydropyrimidine as the drug of choice for the prevention of paraprosthetic seromas in breast reconstructive surgery: A retrospective study |
(Rus)
|
| 卷 25, 编号 4 (2023) |
CLINICAL ONCOLOGY |
The use of hydroxyethyldimethyldihydropyrimidine to improve regeneration processes in a postoperative wound after sectoral resection of the breast |
(Rus)
|
| 卷 26, 编号 1 (2024) |
Articles |
Hereditary forms of breast malignant neoplasms: prognosis, screening and prevention. A review |
(Rus)
|
| 卷 26, 编号 1 (2024) |
Articles |
Efficacy and safety of alpelisib in patients with HR+HER2-negative metastatic breast cancer in real clinical practice: Results of a single-center observational retrospective study |
(Rus)
|
